Introduction
Osteomyelitis and septic arthritis continue to be major problems in orthopaedic surgery. Prosthetic joint replacement has compounded the difficulties, allowing bacteria of low virulence with multiple antibiotic resistances to cause infection and often joint failure. Infections with methicillinresistant Staphylococcus aureus (MRSA), methicillin-resistant Staphylococcus epidermidis (MRSE) or vancomycin-resistant enterococci (VRE) are real clinical challenges and result in significant morbidity and sometimes mortality. Management of these infections involves aggressive surgical debridement and combination antibiotic therapy. Treatment is usually prolonged, with few opportunities for effective oral therapy and early hospital discharge. In addition, there are increasing concerns over the emergence of glycopeptide resistance in Gram-positive organisms, as well as the difficulties of managing patients intolerant to these agents.
Linezolid is the first of the oxazolidinone group of synthetic antibiotics. 1 It has excellent oral bioavailability and activity against clinical isolates of staphylococci and enterococci, including strains resistant to β-lactams and glycopeptides, 2 suggesting a potential role in the management of bone and joint infections.
To date, linezolid has been shown to be effective in a variety of infections caused by Gram-positive cocci, including those where the use of glycopeptide antibiotics was not tolerated. 3 Currently there are no published data regarding the penetration of linezolid at steady state into osteo-articular tissues. Herein we describe the distribution of linezolid into such tissues in volunteers undergoing primary total knee arthroplasty.
Materials and methods

Subjects
Approval for the study was granted by the West Ethics Committee (Greater Glasgow Health Board). Ten patients (five male, five female) with a mean age of 78 years (range 71-88 years) undergoing primary total knee arthroplasty for osteoarthritis (nine) and rheumatoid arthritis (one) were recruited. All gave informed written consent. Their mean weight was 67.6 kg (range 44.5-93 kg) and mean serum creatinine was 105 µmol/L (range 73-161 µmol/L). The exclusion criteria were linezolid hypersensitivity, uncontrolled hypertension, severe hepatic or renal impairment, psychiatric disorder, haematological malignancy or myelosuppression, 
Drug administration
Patients were given linezolid 600 mg orally 12 hourly for 48 h before surgery. The final 600 mg dose was given intravenously 1 h before induction of anaesthesia. Routine antibiotic prophylaxis with intravenous cefuroxime (1.5 g) was given 20 min before inflation of the tourniquet.
Sampling
Total knee replacement was carried out in all patients with a tourniquet applied immediately after induction of anaesthesia. Samples of serum, synovial fluid, synovium, muscle and cancellous bone were collected 30 min after induction. Samples were frozen at -70°C prior to assay.
Drug assay
Linezolid was extracted from tissue samples using the method described by Andrews. 4 Briefly, tissue samples were ground, weighed, mixed with twice the volume of phosphate-buffered saline and placed at 4°C for 5 h, for drug extraction. After centrifugation (2000 rpm for 10 min), the supernatant was removed, mixed with acetonitrile (50:50) and centrifuged for a further 5 min. Serum samples were also prepared for assay in this way.
Linezolid was quantified in serum and tissue by HPLC. 5 A 20 µL injection volume was used. The stationary phase was Hypersil 5ODS, 10 cm × 4.6 mm (HPLC Technology Ltd, Macclesfield, UK). The mobile phase was 1% orthophosphoric acid, 30% methanol, 2 g/L 1-heptane sulphonic acid, adjusted to pH 5 by the addition of 10 M sodium hydroxide. The pump flow rate was 1.0 mL/min. Detection was by UV absorbance (λ max 254 nm). Linezolid recovery from tissue samples was 100% in an evaluation study. 6 The linezolid retention time was ∼6 min and cefuroxime caused no chromatographic interference. 5 The intra-day reproducibility, expressed as the standard deviation/mean × 100, was <6% for quality-control samples containing 5, 15 or 30 mg/L linezolid. The inter-day reproducibility was <12.5%.
Results
Linezolid was well tolerated by all patients. The linezolid concentrations in the different tissues and fluid at 90 min following the final dose are shown in Table 1 . Linezolid penetrated well into all compartments, achieving concentrations of >4 mg/L (the MIC 90 for susceptible Gram-positive organisms 7 ) in all but one of the specimens. The mean synovial fluid, synovium, muscle and bone penetration was 91.9%, 82.2%, 83.5% and 40.1% of the corresponding serum concentration, respectively ( Table 2 ). There were no significant differences in the inflammatory indices of all but one patient with rheumatoid arthritis [erythrocyte sedimentation rate (ESR) 54, range 2-26; C-reactive protein (CRP) 32, range ≤10]. Overall, there was no correlation between patient weight or renal function and the linezolid concentration in serum, synovial fluid or muscle. However, the single patient with a linezolid concentration in bone of <4 mg/kg (3.3 mg/kg) was significantly heavier (93 kg) than the others (weight range 44.5-82 kg). This patient also had a lower concentration of linezolid in synovium (9 mg/kg, range for the other patients 12.3-25.5 mg/kg). However, for this patient, the linezolid concentrations in other compartments, including serum, were similar to those of the other patients (serum 18.6 mg/L, range for others 15.9-34.9 mg/L).
Discussion
Linezolid is a recently licensed synthetic antimicrobial agent with excellent oral bioavailability and activity against many multidrug-resistant Gram-positive organisms, including MRSA, MRSE, penicillin-resistant pneumococci and VRE. Its high bioavailability has contributed to a reduction in the requirement for parenteral therapy (and hence the length of hospital stay) in patients with suspected or proven MRSA infection. 8 Recent reports have described the successful use of linezolid in patients with complex multidrug-resistant Gram-positive infections, including orthopaedic infections. 9 Longer-term outcome data on such patients are awaited with interest. Since most clinical studies of linezolid have been over less than 2 weeks of therapy, little is known about longterm toxicity. Recently, a small number of cases of reversible myelosuppression has been recorded in patients receiving prolonged therapy. 10 Lovering et al., 6 in a recently published study, found that linezolid penetrates rapidly into bone, fat and muscle of patients undergoing hip arthroplasty. The linezolid concentrations achieved were in excess of its MIC 90 for susceptible organisms (4 mg/L) following administration of a single pre-operative intravenous 600 mg dose. However, we are unaware of any data describing the steady-state distribution of linezolid into osteo-articular tissues in humans. Our study in healthy, but elderly, patients has demonstrated that at steady state, linezolid penetrates osteo-articular tissues well. Synovial fluid, synovium, muscle and bone penetration was 91.9%, 82.1%, 83.5% and 40.1%, respectively. In all but one patient, concentrations above the MIC 90 for Gram-positive organisms were achieved in bone. This particular patient attained a high concentration of linezolid in all tissues except bone and synovium. This may have been due to his significantly heavier body mass compared with other patients.
It would seem prudent that linezolid should be reserved for treatment of multidrug-resistant Gram-positive bone and joint infections, such as MRSA, coagulase-negative staphylococci and resistant enterococci, when patients are intolerant of glyopeptide agents. Factors likely to encourage the development of linezolid resistance in established VRE and MRSA infections are prolonged therapy, failure to remove an infected device and, probably, suboptimal concentrations of linezolid in target sites. Clearly, these risk factors are relevant for patients with bone and prosthetic joint infections and should be considered when prescribing any antibiotic or combination of antibiotics.
In conclusion, our data suggest adequate penetration of linezolid into osteo-articular tissues and fluid. Linezolid may be a useful agent in the management of multidrug-resistant Gram-positive bone and joint infections as well as deepseated soft-tissue infections; however, further clinical studies are required to prove its efficacy in such cases. 
